PMID- 19281071
OWN - NLM
STAT- MEDLINE
DCOM- 20090326
LR  - 20211020
IS  - 1176-9106 (Print)
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Linking)
VI  - 3
IP  - 4
DP  - 2008
TI  - Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: 
      efficacy and safety.
PG  - 521-9
AB  - COPD is characterized by progressive airflow obstruction which does not fully 
      reverse to inhaled or oral pharmacotherapy. The management of patients with COPD 
      has taken a totally new direction over the past 20 years, thank to the use of 
      novel therapies aimed to improve and modify the natural history of COPD. 
      Long-acting bronchodilators, including long-acting beta2-agonists (LABAs), were 
      introduced several years ago in order to enhance improvements in lung function, 
      health status related quality of life, and reduce the rate of exacerbations. 
      These effects can be boosted by the combination of LABAs with long-acting 
      anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly 
      well tolerated although adverse effects such as tremor and palpitations are 
      occasionally troublesome.
FAU - Rossi, Andrea
AU  - Rossi A
AD  - Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy. 
      arossi@ospedaliriuniti.bergamo.it
FAU - Khirani, Sonia
AU  - Khirani S
FAU - Cazzola, Mario
AU  - Cazzola M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Cholinergic Antagonists)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Adrenergic beta-2 Receptor Agonists
MH  - Adrenergic beta-Agonists/administration & dosage/adverse effects/*therapeutic use
MH  - Airway Resistance/drug effects
MH  - Animals
MH  - Bronchodilator Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Cardiovascular System/drug effects
MH  - Cholinergic Antagonists/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Oxygen/blood
MH  - Practice Guidelines as Topic
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
MH  - Pulmonary Gas Exchange/drug effects
MH  - Treatment Outcome
PMC - PMC2650610
EDAT- 2008/01/01 00:00
MHDA- 2009/03/27 09:00
PMCR- 2009/04/01
CRDT- 2009/03/14 09:00
PHST- 2009/03/14 09:00 [entrez]
PHST- 2008/01/01 00:00 [pubmed]
PHST- 2009/03/27 09:00 [medline]
PHST- 2009/04/01 00:00 [pmc-release]
AID - copd-3-521 [pii]
AID - 10.2147/copd.s1353 [doi]
PST - ppublish
SO  - Int J Chron Obstruct Pulmon Dis. 2008;3(4):521-9. doi: 10.2147/copd.s1353.